Daily Respiratory Research Analysis
Three impactful respiratory studies stood out today: a multicenter ICU RCT showed that adding rapid multiplex PCR to a procalcitonin-guided algorithm did not improve the primary endpoint but modestly shortened total antibiotic exposure in severe community-acquired pneumonia. A single-cell atlas of post-tuberculosis human lung revealed endothelial thromboinflammation and reduced FOXO3 signaling as mechanistic drivers of irreversible damage. A large derivation–validation study produced the CHAMPIO
Summary
Three impactful respiratory studies stood out today: a multicenter ICU RCT showed that adding rapid multiplex PCR to a procalcitonin-guided algorithm did not improve the primary endpoint but modestly shortened total antibiotic exposure in severe community-acquired pneumonia. A single-cell atlas of post-tuberculosis human lung revealed endothelial thromboinflammation and reduced FOXO3 signaling as mechanistic drivers of irreversible damage. A large derivation–validation study produced the CHAMPION-ALERT score that accurately predicts in-hospital mortality for COPD exacerbations and outperforms existing tools.
Research Themes
- Antimicrobial stewardship in severe pneumonia
- Risk stratification and prognosis in COPD exacerbations
- Pathophysiology of post-tuberculosis lung injury (endothelial thromboinflammation)
Selected Articles
1. A single-cell transcriptomic atlas reveals senescence and inflammation in the post-tuberculosis human lung.
This single-cell atlas of post-TB human lungs uncovers pervasive senescence and inflammation signatures across cell types, with endothelial thromboinflammation and reduced FOXO3 signaling as central features. Experimental perturbations (FOXO3 siRNA, thrombin) in pulmonary endothelial cells validated causal links to senescence and inflammatory activation.
Impact: Revealing endothelial thromboinflammation and FOXO3 pathway suppression provides mechanistic targets to mitigate post-tuberculosis lung damage. The single-cell approach across human tissues represents a rigorous and comprehensive resource for future translational studies.
Clinical Implications: Therapeutic strategies that restore FOXO3 signaling or dampen NF-κB–driven thromboinflammation in pulmonary endothelium may help limit progressive post-TB lung impairment. The atlas prioritizes cell types and pathways for drug development and biomarker discovery.
Key Findings
- Single-cell RNA-seq of 19 post-TB and 13 control lungs revealed signatures of senescence, inflammation, fibrosis, and apoptosis across multiple cell types.
- Vascular inflammation was a defining feature of post-TB tissue with decreased FOXO3 signaling and increased NF-κB–dependent thromboinflammation.
- In pulmonary endothelial cells, FOXO3 silencing and thrombin exposure exacerbated senescence and inflammatory activation, validating mechanistic links.
Methodological Strengths
- Human-tissue single-cell transcriptomics across lesion-adjacent regions with matched controls
- Mechanistic validation via FOXO3 siRNA and thrombin treatment in pulmonary endothelial cells
Limitations
- Cross-sectional tissue analysis limits causal inference regarding temporal disease progression
- Modest sample size and potential heterogeneity of lesion chronicity and prior treatments
Future Directions: Prospective studies to test endothelial-targeted anti-thromboinflammatory or FOXO3-restoring interventions; integrate spatial transcriptomics and longitudinal sampling to map progression and therapeutic response.
Patients with a history of Mycobacterium tuberculosis infection often suffer from irreversible and progressive pulmonary damage, yet the underlying mechanisms are not fully understood. Here we conducted single-cell transcriptomic analysis of human lung tissues including 19 post-tuberculosis lung tissues and 13 matched normal lung samples as controls, focusing on areas within and surrounding tuberculosis lesions. We identified tuberculosis-associated molecular signatures across various cell types, including gene expression patterns associated with senescence, inflammation, fibrosis and apoptosis. We observed increased vascular inflammation as a key feature of lung tissues following tuberculosis. Signatures of decreased FOXO3 signalling and increased NF-κB-dependent thromboinflammation were validated by showing that small interfering RNA silencing of FOXO3 and thrombin treatment exacerbated senescence and inflammation in pulmonary endothelial cells. These findings provide insight into the mechanisms contributing to post-tuberculosis pulmonary damage and suggest potential therapeutic targets for alleviating lung impairment in these patients.
2. Combined use of a multiplex PCR and serum procalcitonin to reduce antibiotic exposure in critically ill patients with community-acquired pneumonia: the MULTI-CAP randomized controlled trial.
In this 20-center RCT (n=406), adding rapid respiratory mPCR to a procalcitonin-guided algorithm did not increase days alive without antibiotics by day 28 in ICU CAP, but reduced cumulative antibiotic duration by 3 days without safety signals. The trial refines expectations for syndromic testing in stewardship strategies.
Impact: High-quality randomized evidence directly informs ICU stewardship: rapid syndromic diagnostics plus procalcitonin does not alter the primary outcome but modestly reduces total antibiotic exposure.
Clinical Implications: Adopting respiratory mPCR within procalcitonin-guided pathways may not change day-28 antibiotic-free survival but can shorten total antibiotic days. Programs should prioritize timely de-escalation and consider resource allocation to mPCR where modest duration reductions are valuable.
Key Findings
- Primary endpoint (days alive without antibiotics by day 28) was identical between groups (median 19 days; difference 0.0, 95% CI −4.0 to 4.0).
- Cumulative antibiotic duration through day 28 was reduced by 3 days (95% CI −5.1 to −0.9) with mPCR plus procalcitonin.
- Serious adverse events were similar, supporting safety of the stewardship algorithm.
Methodological Strengths
- Multicenter randomized design with protocolized stopping/de-escalation using serial procalcitonin
- Intention-to-treat analysis and clinically relevant primary endpoint
Limitations
- Open-label design may influence co-interventions and decision-making
- Primary outcome neutral; findings may be context-dependent on local microbiology and stewardship practices
Future Directions: Evaluate patient-centered outcomes (e.g., resistance emergence, Clostridioides difficile), cost-effectiveness of mPCR integration, and adaptive strategies targeting high-yield subgroups.
PURPOSE: Multiplex polymerase chain reaction (mPCR) testing has the potential to rapidly and accurately identify causative microorganisms in patients with community-acquired pneumonia (CAP). Its use in a management strategy, along with biomarkers, may reduce antibiotic exposure and improve clinical outcomes. METHODS: The MULTI-CAP trial was a multicenter (n = 20), parallel-group, superiority, open-label, randomized trial. Subjects were non-immunocompromised adult patients (≥ 18 years) admitted to the intensive care unit (ICU) for CAP and randomly assigned in a 1:1 ratio. In the intervention group, the microbiological diagnosis combined a broad-spectrum respiratory mPCR and conventional microbiological investigations. An algorithm for early discontinuation or de-escalation of antibiotics was applied, based on mPCR results and serum procalcitonin. In the control group, only conventional microbiological investigations were performed. In both groups, antibiotic discontinuation was considered on Day 3 and day after day until Day 7, based on procalcitonin values and kinetics. The primary endpoint was defined as the number of days alive without any antibiotic from the time of enrollment to Day 28. RESULTS: From October 4, 2018, to March 3, 2022, 406 patients were randomized, and 385 were evaluable in the intention-to-treat analysis. The median number of days alive without antibiotics on Day 28 was 19.0 (0.0; 24.0) days in the intervention group and 19.0 (7.0; 22.0) days in the control group (difference, 0.0 (95% CI, - 4.0 to 4.0). However, the antibiotic cumulative duration on day 28 was 3 days shorter (95% CI, - 5.1 to - 0.9) in the intervention group. Serious adverse events did not differ between groups. CONCLUSION: In ICU patients with CAP, a management strategy combining a mPCR and serum procalcitonin failed to reduce antibiotic exposure or improve outcomes on Day 28, compared to usual care. TRIAL REGISTRATION NUMBER: NCT03452826 (March 2018), EudraCT 2017-A01615-48.
3. Derivation and Validation of a New Score for Predicting In-Hospital Mortality in Exacerbations of Chronic Obstructive Pulmonary Disease.
The CHAMPION-ALERT score (11 routinely available variables) predicted in-hospital mortality in ECOPD with AUC 0.89 in derivation and external validation cohorts, outperforming or matching DECAF, BAP-65, and CURB-65. Risk strata (0–5, 6–9, 10–16) corresponded to mortality of 0.3%, 4.4%, and 25.9%.
Impact: A robust, externally validated, bedside prognostic tool can standardize triage, inform level-of-care decisions, and benchmark quality for COPD exacerbation hospitalizations.
Clinical Implications: Clinicians can use CHAMPION-ALERT at admission to guide ICU referral, monitoring intensity, escalation plans, and goals-of-care discussions, while facilitating risk-adjusted outcomes and resource allocation.
Key Findings
- An 11-variable score (CHAMPION-ALERT) achieved AUC 0.89 (95% CI 0.87–0.92) for in-hospital mortality in 14,007 derivation patients.
- External validation (n=3,048) reproduced high discrimination; risk tiers mapped to 0.3%, 4.4%, and 25.9% mortality.
- Performance surpassed or matched DECAF, BAP-65, and CURB-65, using variables available at admission.
Methodological Strengths
- Large multicenter derivation with prospective external validation
- Direct comparison with established prognostic scores (DECAF, BAP-65, CURB-65)
Limitations
- Geographic concentration in China may limit generalizability without international validation
- In-hospital mortality endpoint does not capture post-discharge outcomes
Future Directions: Validate CHAMPION-ALERT internationally, assess calibration across healthcare systems, and test clinical impact through implementation studies and EHR integration.
BACKGROUND AND OBJECTIVE: Since exacerbation of chronic obstructive pulmonary disease (ECOPD) is both common and often fatal, accurate prognostication of patients hospitalized for ECOPD is critical. We aimed to develop and validate a new score for predicting hospital mortality. METHODS: Independent predictors of in-hospital mortality were identified from a large prospective cohort of ECOPD from 10 medical centers in China between September 2017 and July 2021, and incorporated into a clinical prediction score. Application of this score was then prospectively evaluated in an external validation cohort. The prognostic value of the scores was assessed by the area under the receiver operating characteristic curve (AUC). RESULTS: A total of 14,007 patients were included in the derivation cohort, and 201 patients (1.43%) died in the hospital. The 11 strongest independent predictors were combined to form the Chronic Heart failure, Age ≥ 75, altered Mental status, Pneumonia, Interstitial lung disease, diastolic blOod pressure ≤ 70 mmHg, Neutrophil ratio > 85 (%), Anemia, Long-term bed rest, hEart Rate > 100 (beats/minute), and blood urea niTrogen > 7.3 mmol/L, CHAMPION-ALERT Score, which enabled patients to be stratified according to increasing risk of in-hospital mortality: score 0-5, 0.3%; score 6-9, 4.4%; score 10-16, 25.9%. The score displayed excellent predictive value for mortality with an AUC of 0.89 (95% CI 0.87-0.92), which was reproduced in the validation cohort of 3048 patients. The discrimination of the new score was superior to or comparable to that of existing prognostic scores (DECAF, BAP-65, and CURB-65). CONCLUSION: A new scoring system composes of 11 routinely available clinical variables on admission can accurately predict in-hospital mortality in ECOPD and shows a trend toward better performance compared to previous prognostic scores.